Filing Details

Accession Number:
0001209191-21-054758
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-09-03 16:25:06
Reporting Period:
2021-09-01
Accepted Time:
2021-09-03 16:25:06
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1679082 Myovant Sciences Ltd. MYOV Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1690298 Terrie Curran C/O Myovant Sciences Inc.
2000 Sierra Point Parkway
Brisbane CA 94005
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Shares Acquisiton 2021-09-01 11,373 $7.65 11,373 No 4 M Direct
Common Shares Disposition 2021-09-01 11,373 $25.00 0 No 4 S Direct
Common Shares Acquisiton 2021-09-02 37,135 $7.65 37,135 No 4 M Direct
Common Shares Disposition 2021-09-02 37,135 $25.03 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Shares Stock Option (Right to Buy) Disposition 2021-09-01 11,373 $0.00 11,373 $7.65
Common Shares Stock Option (Right to Buy) Disposition 2021-09-02 37,135 $0.00 37,135 $7.65
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
47,235 2029-08-23 No 4 M Direct
10,100 2029-08-23 No 4 M Direct
Footnotes
  1. Shares sold pursuant to a 10b5-1 trading plan.
  2. The shares were sold at prices ranging from $25.00 to $25.01. The reporting person will provide to the SEC, the issuer or security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The shares were sold at prices ranging from $25.00 to $25.10. The reporting person will provide to the SEC, the issuer or security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. Fully vested.